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Xenotransplantation
Xenotransplantation is defined as the transplan-
tation of tissues or cells between two zoologi-
cally different species. Due to the shortage of
human organs for allotransplantation, i.e. trans-
plantation between humans, essential efforts
aimed at development of a donor for animal-hu-
man xenotransplantation have been performed
over the last decade.
Rejections caused by xenotransplantation
Transplantation between two different species
may give rise to two types of graft rejection. Be-
tween so-called discordant species a hypera-
cute rejection (HAR) occurs within minutes or
hours. In so-called concordant species this type
of rejection does not occur, but over days a de-
layed xenograft rejection (DXG) (6) will occur.
In all transplanted organs, xeno- as well as allo-
transplanted, chronic graft rejection (CRG) will
occur after years.
Man is concordant with old world primates, but
due to several reasons, such as breeding diffi-
culties, risk of retroviral epidemics, concerns
for the use of endangered species, etc., the dis-
cordant pig is considered the donor of choice.
HAR is primarily caused by initiation of the
complement cascade. The antigen known to be
activating the classical pathway is the alpha-gal
epitope (10) (Figure 1); the epitope alternative
to the primate AB0 blood group system in most
non-primate mammals. In species, in which the
antigen is absent, circulating antibodies are pre-
sent. In humans IgG against the alpha-gal epi-
tope counts for up to a total of 1% of circulat-
ing IgG (11). These antibodies probably derive
from a reaction to members of the intestinal
flora, especially Enterobacteriaceae spp., but
also other types of infectious agents possess the
alpha-gal epitope as a structural element in
their cell walls (10).
Strategies to prevent rejection
Acute rejections after allotransplantation are
generally prevented by immunosuppressive
treatment, but although HAR may be prevented
by cobra snake venom (12) and certain comple-
ment regulatory immunocomponents (27), it
seems unlikely that complement cascade acti-
vation can be prevented by the same means
without seriously interfering with the health
and well-being of the recipient. Therefore, the
donor or source animal needs to be modified to
prevent recognition of complement-activating
antigens. Transgenic techniques are the tools
for this.
Inserting genes
Insertion of genes may be done by the pronu-
cleus microinjection method (14), which func-
tions well in a range of animal species, includ-
ing pigs. Three types of genes may be attractive
to insert in a xenograft donor. The H-trans-
ferase, which fucosylates N-acetyl-lactosamine
in competition with the gal-transferase (Figure
1), has been inserted in both mice (5, 28) and
pigs (20, 28). Cells of H-transferase transgenic
animals show higher resistance towards human
sera (20, 28), but in the mice produced by Chen
and coworkers (5), it was found that although
the alpha-gal epitope was only eliminated in
those cells, in which it was also low in non-
transgenic mice. Furthermore, it has been im-
possible to produce homozygotic H-transferase
animals (21), i.e. too high an expression of the
H-transferase in gal transferase producing ani-
mals seems to be toxic. The mechanisms be-
hind this are not fully known, but lectin binding
studies show that the structure of the cell walls
of H-transferase transgenic animals is changed
far beyond the sole deficit of the alpha-gal epi-
tope and presence of the H antigen. Some crypt
antigen, Tn and Forssman, may even become
exposed on the cellular wall, which may in-
crease the risk of DXG of organs from a H-
transferase transgenic donor (23). This reduces
the likelihood of such a transgenic animal be-
coming a future xenograft donor. Another ap-
proach attempted in mice is to insert genes cod-
ing for the enzyme, alpha-1,3-galatosidase,
which resynthesises the alpha-gal epitope into a
compound not attacked by natural antibodies
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F i  g  u  r  e  1 . Synthesis of the α-gal epitope.
N-acetyllactosamine is in most mammals converted to the alpha-gal epitope by the gal-transferase. In certain pri-
mate species, including humans, N-acetyllactosamine is converted to the H-subtance by the H-transferase and
by the A- or B-transferases further on to the epitopes of the AB0 blood groups, i.e. either the A or B substances,
respectively. Strategies for xenoacceptance of porcine organs in humans would be removal of the gal-transferase
or introduction of the human H-transferase in the transplanted organ. 
produced by humans. These mice tended to se-
crete more proteins in the urine than the wild
type. Furthermore, low body weights, partial
damage to hair growth and early death occurred
more frequently (19). Therefore, neither does
this approach seem to be applicable for the pro-
duction of a xenograft source animal.
A third and more successful approach may be to
insert genes, which identify the tissue as homo-
logue to the complement system. Therefore, it
binds parts of the proteins involved in the com-
plement cascade, thereby disabling both the
classical and the alternative pathway, so-called
complement-regulatory factors (CRF) (Figure
2). The most important ones in xenotransplan-
tation research are human decay accelerating
factor (H-DAF), membrane cofactor protein
(MCP) and CD 59. Both mice and pigs trans-
genic for CRF's have been produced, and the
transgenic animals have been combined with
one another and with animals changed on al-
pha-gal related genes. 
Knock-outing genes
To knock-out loci for the upstart of a transgenic
source animal colony demands the use of the
embryonic stem cell method for transfection
(15); a method, which so far is only available in
mice. However, pig cloning and nuclear transfer
techniques (9) represent a reasonable alterna-
tive. Two groups reported the successful pro-
duction of alpha-gal knock out mice in the mid-
nineties (30), and around New Year 2002/2003
two other groups reported the successful pro-
duction of alpha-gal knock out pigs by cloning
and nuclear transfer (8, 21). Although those
pigs appearing in these two publications were
hemizygotic, one of these groups has, by
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F i  g  u  r  e   2 . Possible pathways for complement activation; the key factor for hyperacute rejection (HAR). 
The classical pathway is activated by the presence of a specific antigen. In xenografts in humans this is the al-
pha-gal epitope against which humans have natural antibodies. The alternative pathway is normally activated by
some non-specific cell surface structures, but activation of this pathway against xenografts may be prevented if
the xenograft contains either membrane cofactor (MCP or CD 46) or decay accellerating factor (H-DAF or CD
55), which both prevent conversion of C3 to C5 or CD 59, which prevents the C6 C7 C8 C9 cascade.
cloning of cells from these pigs, successfully
produced homozygotic alpha-gal knock out
pigs, which seem to be fully viable (2).
Transplantation experiments from pigs to
primates
The baboon, and to a lesser extent the rhesus
monkey, are the animals of choice for mod-
elling pig to human xenotransplantation. Trans-
plantation of non-transgenic pig organs to these
primates results in HAR within hours (24).
Transplantation from CRF transgenic pigs to
baboons has been attempted, primarily with the
heart (1) and kidney (7) and it is evident that
CRF's prevent HAR, while DXG occurs within
one or two weeks (1, 4). Grafts become infil-
trated by macrophages, T cells and B cells and
the recipients develop thrombocytopenia and
abnormalities in coagulation (7). Supplemen-
tary supportive treatments of recipients with
antithymocyte serum (31), C1 inhibitor or cy-
clophosphamide may prolong graft survival up
to 40 days (13). Extracorporal perfusion using
CRF transgenic pig liver cells seem to offer an
improvement compared to perfusion using non-
transgenic pig cells (26). Results of transplan-
tation of organs from alpha-gal knock out pigs
to primates have not yet been published.
Xenozoonosis
The term xenozoonosis covers infections that
may spread from the transplanted organ to the
recipient. One might fear that ordinary zoonotic
infections known to be present in pigs, such as
encephalymyocarditis virus (3) and rotaviruses
(17) may pose a risk for the recipients, but these
infections are easy to handle during the animal
production phase and would in any case mostly
be a risk to the individual; a risk, that probably
would be outweighed by the benefits from
xenotransplantation.
Much more concern has been related to the risk
of activating porcine endogenous retroviruses
(PERV) in the recipients, which hereafter may
spread the infection to relatives and, thereby,
cause a world-wide retroviral epidemic. The
discussion was initiated by the experience that
retrovirus produced by the PK-15 kidney cell
line (PERV-PK) infected human kidney 293
cell lines and co-cultivation of X-irradiated PK-
15 cells with human cells resulted in a broader
range of human cell infection, including human
diploid fibroblasts and B- and T-cell lines (25).
Host range analyses have shown that type A and
B PERV Env's have wider host ranges including
several human cell lines, compared with type C
PERV, which infect only one human cell line
(29). However, in a retrospective study 15 im-
munosuppressed baboons were tested for a spe-
cific immune response against PERV after
transplantation of porcine endothelial cells,
mononuclear blood cells, and lungs. Anti-
PERV antibody expression was analyzed with
peptide-based, enzyme-linked immunosorbent
assays and highly sensitive Western Blot assay
showing no evidence of PERV specific humoral
immune response (22). Retrospective studies of
patients exposed to living pig tissues have nei-
ther been able to show such cross species trans-
mission (18).
Functional problems related to 
xenotransplanted organs
Physiological and anatomical differences be-
tween man and pig may be speculated to be ob-
structive for successful xenotransplantation in
various ways. E.g. man is the only animal living
in an upright position, and therefore gravity
may have a different impact on the lung, heart,
liver, and kidney. Differences on the humoral
and enzymatic basis may be even more pro-
nounced. Hormones and enzymes are regulated
by complicated and often species-specific
mechanisms, e.g. growth hormones may stimu-
late the xenografts to unrestricted growth. If en-
zymes are not removed by the liver they may
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reach a level not compatible with life. Products
like albumin are carriers for other molecules
and need to be compatible for binding sites. Es-
sential porcine and human proteins differ sig-
nificantly, e.g. albumin have an amino acid
identity of less than 65%, erythropoetin (EPO)
of less than 82%, and complement of less than
70% (16). Therefore, especially the liver at pre-
sent seems to be an unlikely candidate for xeno-
transplantation.
Future perspectives of xenotransplantation
The production of the alpha-gal knock out pig
has been a major step-forward in xenotrans-
plantation research. Although the road towards
xenotransplantation still seems long, especially
for complicated organs such as the liver, the
fact that research in the future may be more di-
rected against DXG, which may be handled by
other means than transgenesis, e.g. immuno-
suppression, gives rise to optimism. Also,
xenotransplantation with transgenic organs
may in the future offer a higher quality of trans-
plantation if the organs could be modified in
such a way, that all types of rejection could be
omitted, thus avoiding the life-long treatment
with immunosuppressives,
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